Podium to Practice: Chicago 2025 – GU: NIAGARA
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
4503 – Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
This program has been made possible through unrestricted support from Ipsen.
Studies/trials discussed:
4503 – Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
199 Bay Street #4000
Toronto, ON M5L 1A9
©2025 OncologyEducation a Think Research company. All rights reserved. Privacy Policy. Privacy Notice. Accessibility Statement.
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.